Clinical Evaluation of Ganoderma lucidum Spore Oil for Triglyceride Reduction: A Randomized, Double-Blind, Crossover Study

<b>Background</b>: <i>Ganoderma lucidum</i> spore oil (GLSO) is widely recognized for its notable medicinal and nutritional properties. This study aimed to systematically evaluate the efficacy and safety of GLSO extract in individuals with dyslipidemia. <b>Methods</b>: In a randomized, double-blind, placebo-controlled trial, 110 participants were enrolled and randomly assigned to either the intervention group or the placebo group. A chi-square test of baseline characteristics confirmed no significant differences in age or sex distribution between the two groups. <b>Results</b>: After 12 weeks of intervention, the intervention group exhibited significantly lower levels of total cholesterol (CHO), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), alongside significantly higher levels of high-density lipoprotein cholesterol (HDL-C), compared to the placebo group, with all differences reaching statistical significance. Furthermore, the relative percentage changes in lipid parameters also demonstrated significant intergroup differences. Safety analyses revealed that the intervention had no notable effects on renal function parameters, whereas hepatic function parameters showed statistically significant improvement in the intervention group. <b>Conclusions</b>: This study demonstrated that GLSO extract effectively improved lipid profiles and liver function, with a favorable safety and tolerability profile. These findings strongly support the potential clinical application of GLSO extract in the management of dyslipidemia.